


FACT SHEET

Protein degraders: from discovery to development

Targeted protein degradation has emerged as a transformative approaching drug discovery, enabling the selective elimination of disease-associated proteins using the ubiquitin-proteasome system. Modalities such as protein degraders and molecular glues have the potential to provide therapeutic solutions for previously “undruggable” targets and offer mechanisms to overcome resistance to traditional small molecule inhibitors. Given the complexity, innovative and tailored strategies are needed at every step of the process. By partnering with Curia, you access more than a decade’s worth of experience in protein degrader research & development to help fast-track your journey to the clinic.



Leverage Curia’s expertise to advance your candidate from discovery to development, including:

- Process evaluation and route familiarization
- Process optimization and intermediate prep
- Non-GMP synthesis of API
- Manufacture under GMP of API or DP
- Reporting and data transfer